Bulletin
Investor Alert

New York Markets Open in:

June 16, 2004, 5:52 p.m. EDT

Biogen, Genentech release drug data

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Ginkgo Bioworks Holdings Inc. (DNA)
  • X
    Biogen Inc. (BIIB)
  • X
    Roche Holding AG Part. Cert. (RHHVF)

or Cancel Already have a watchlist? Log In

By Val Brickates Kennedy, CBS.MarketWatch.com

BOSTON (CBS.MW) -- Genentech, Biogen Idec and Swiss drug giant Roche jointly published positive Phase II clinical trial results Wednesday that showed Genentech's Rituxan was effective in treating moderate-to-severe cases of rheumatoid arthritis.

The three companies are testing Rituxan for rheumatoid arthritis in combination with the drug methotrextate. The results appear in the current issue of the New England Journal of Medicine. Phase III clinical trials for the therapy have already begun.

Rituxan is approved in the U.S. to treat non-Hodgkin's lymphoma. The drug is marketed by Genentech /zigman2/quotes/226092395/composite DNA -4.07% and Biogen Idec /zigman2/quotes/201531540/composite BIIB +1.37% in the U.S., and by Roche /zigman2/quotes/206948568/composite RHHVF +3.82% in all other nations except Japan.

/zigman2/quotes/226092395/composite
US : U.S.: NYSE
$ 13.21
-0.56 -4.07%
Volume: 6.18M
Oct. 21, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$26.95 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/201531540/composite
US : U.S.: Nasdaq
$ 270.21
+3.64 +1.37%
Volume: 1.37M
Oct. 21, 2021 4:00p
P/E Ratio
26.43
Dividend Yield
N/A
Market Cap
$39.73 billion
Rev. per Employee
$1.36M
loading...
/zigman2/quotes/206948568/composite
US : U.S.: OTC
$ 393.00
+14.46 +3.82%
Volume: 626.00
Oct. 21, 2021 3:55p
P/E Ratio
22.01
Dividend Yield
0.00%
Market Cap
$333.14 billion
Rev. per Employee
$612,402
loading...

Val Brickates Kennedy is a reporter for CBS MarketWatch based in Boston.

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

World News from MarketWatch

Link to MarketWatch's Slice.